Adenoviral-based vaccine promotes neoantigen-specific CD8 + T cell stemness and tumor rejection By ef Posted 09/27/2022 In Scientific publications Adenoviral-based vaccine promotes neoantigen-specific CD8 + T cell stemness and tumor rejection2022-09-272022-09-27http://www.nouscom.com/wp-content/uploads/2018/03/artboard-3.pngNouscomhttp://www.nouscom.com/wp-content/uploads/2018/03/artboard-3.png200px200px D’Alise AM et al. Sci Transl Med 2022 Read article Recent PostsNouscom Raises €67.5 million ($72 million) in Oversubscribed Series C Financing RoundDr. Morena D’Alise (VP of Immunology) is presenting at the SITC Annual Meeting 2023, San Diego November 1-3Dr. Elisa Scarselli (Nouscom CSO) invited speaker at EHTG European Hereditary Tumour Group 2023, Vilnius September 28 – October 1stDr. Elisa Scarselli (CSO) invited speaker at Vaccines Europe 2023, Berlin September 13-15
